Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.98%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.72 per share when it actually produced a loss of $1.35, delivering a surprise of -87.50%.Over the last four quarters, the com ...